Ahmedabad, Gujarat, India, January 2026 – Cadila Pharmaceuticals Limited has promoted Kamalesh Kalidasan to Chief Operating Officer (COO), expanding his leadership remit to drive end-to-end business performance across the organisation’s multi-vertical branded portfolio. In this role, Kamalesh will own enterprise-wide P&L and operating performance across 10 verticals and therapy areas, spanning multiple divisions and geographies, including Nepal, with a focus on sustainable growth, margin expansion, cash discipline and capital efficiency.
As COO, he is responsible for translating Board and Promoter priorities into executable operating plans across Sales, Marketing, Commercial Operations, Supply Chain and Market Access, while building a future-ready organisation through a strong people strategy. His mandate also includes institutionalising Commercial Excellence and Sales Force Effectiveness (SFE) across go-to-market design, incentive structures, CRM adoption and omnichannel execution—supporting productivity and capability building across 1,000–1,800+ field teams. He will additionally provide enterprise oversight on portfolio strategy, brand P&Ls, lifecycle management and launch excellence, including new product planning, in-licensing, acquisitions and brand integration, while championing analytics-led decision-making, digital transformation and governance aligned to UCPMP standards.
Before this promotion, Kamalesh Kalidasan served as President – Branded SBU’s at Cadila Pharmaceuticals Limited during 2025, leading key branded prescription units and spearheading the launch of specialised innovative ranges across key therapies and OTC products. In this role, his focus included strategic partnerships for expansion and the use of data-driven decision-making to improve product development and marketing effectiveness.
Prior to joining Cadila, Kamalesh spent close to a decade at Cipla, where he held several senior commercial leadership roles. Most recently, he served as Chief Commercial Head & Senior Vice President (Spectrum – Acute & Chronic Therapy Cluster), leading multiple therapy areas and large teams pan-India, with responsibility for market-beating topline growth and profitable P&L delivery, while also shaping portfolio strategy through in-licensing and innovation pathways.
Earlier at Cipla, he served as Vice President (Chronic Therapies), where he led cardio-metabolic strategy and organisational restructuring initiatives to compete in both mature and growth markets. He also held roles as Vice President (Acute & Chronic Therapies) and Business Head (Emerging Specialties Cluster), driving large therapy portfolios and complex go-to-market execution across multiple divisions with sizeable teams and revenue responsibility.
Before Cipla, Kamalesh built strong marketing and portfolio leadership experience at MSD, where he served as Director – Marketing (Diversified Therapies) and earlier as Business Unit Head (Respiratory & Dermatology), managing brand strategy, lifecycle management, new product planning and cross-functional execution while ensuring strong compliance discipline.
His earlier leadership foundation was shaped across Schering-Plough, where he held responsibilities spanning business leadership, sales leadership and country/zone management, including work across India regions and neighbouring markets, building high-performance sales organisations and strengthening ethics, governance and field-force effectiveness.
About Cadila Pharmaceuticals Limited
Founded by Shri I.A. Modi, Cadila Pharmaceuticals Limited is among India’s largest privately held pharmaceutical companies, headquartered in Ahmedabad, Gujarat. Over seven decades, the company has developed and manufactured a wide range of pharmaceutical products in India and sells and distributes them across more than a hundred countries. With a strong focus on innovation and research, Cadila is present across 45+ therapeutic areas and 12 specialities, supported by 300+ scientists across its R&D ecosystem. The company’s manufacturing footprint includes a large formulations facility at Dholka (near Ahmedabad) with USFDA approval, another formulations facility at Samba (Jammu & Kashmir), and two API manufacturing units at Ankleshwar, Gujarat, producing a broad range of APIs and intermediates, including USFDA-certified products.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
